Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases

Our fully integrated R&D engine from target selection through to pivotal studies is powered by our team of world-class researchers with the experience to discover, develop and commercialize our novel agents globally with partners and collaborators.

We thrive on scientific challenges and strive to deliver transformational therapies for patients with difficult-to-treat cancers and other serious diseases. Our growing pipeline of novel multifunctional therapeutics is supported by our best-in-class antibody-drug conjugates and multispecific antibody therapeutics technology platforms.

Zymeworks is a global biotechnology company developing novel, multifunctional therapeutics to address difficult-to-treat cancers and other serious diseases.

We are driven by our mission to make a meaningful difference for people around the world who are impacted by difficult-to-treat cancers and other serious diseases. Our complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics.

Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet medical need.

In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged and validated in product development through strategic partnerships with global biopharmaceutical companies.

Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers.